• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PDS Life Sciences launches SEND Express

PDS Life Sciences launches SEND Express

March 14, 2016
CenterWatch Staff

PDS Life Sciences, a global provider of software and solutions for life sciences research and development, has announced the launch of SEND Express, a turnkey solution for the generation of Standard for Exchange of Nonclinical Data (SEND) datasets.

“With our new SEND Express business unit, PDS has created the only organization and service dedicated to providing outsourced SEND-compliant preclinical data packages harmonized and ready for FDA submission,” said Sayed Badrawi, CEO of PDS. “We have created a proprietary ‘data production line’ with quality systems built in to ensure the highest data integrity and the shortest turnaround times in the industry.”

With its own U.S.-based server infrastructure, PDS SEND Express helps pharmaceutical companies and CROs meet FDA SEND requirements without needing to invest in software and staff training. As a virtual extension of clients’ internal teams, PDS’ preclinical scientists and data analysts use TranSEND, the company’s proprietary software data translation engine, to expedite data integration and harmonization into SEND-compliant datasets. Through the end of March, SEND Express will have been used to successfully transform nearly 100 preclinical datasets for clients across three continents using heterogeneous source data, from PDFs to various LIMs outputs. 

The launch of this platform corresponds with the FDA deadline for standardized electronic data submissions. By Dec. 17, 2016, all datasets from studies supporting new drug applications, biologics license applications and abbreviated new drug applications must be submitted to the FDA in SEND format. 

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing